Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.

Participants needed: 34
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Celyad Oncology SAUpdated: Mar 9, 2022Locations: 5
Eligibility criteria

Histologically proven metastatic adenocarcinoma of the colon or rectum. [+9]

Any other investigational agent or device within 4 weeks of the first study trea... [+8]

Read more
Status: Recruiting

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy

Participants needed: 49
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Celyad Oncology SAUpdated: Nov 20, 2020Locations: 4
Eligibility criteria

Histologically proven metastatic adenocarcinoma of the colon or rectum. [+7]

The patient has a confirmed or history of tumor involvement in the central nervo... [+3]

Read more
Status: Recruiting

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patient. A maximum of 27 r/r AML/MDS patients will be evaluated in this study in case of no dose limiting toxicity (DLT) and no replacement of patients.

Participants needed: 27
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Celyad Oncology SAUpdated: Jun 9, 2020Locations: 5
Eligibility criteria

A confirmed relapsed or refractory acute AML (i.e. ≥ 5% blasts in bone marrow or... [+12]

Patients with a confirmed or history of tumor involvement in the central nervous... [+7]

Read more